PANWARFIN
LOE ApproachingNDAORALTABLET
Approved
Aug 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PANWARFIN is an oral anticoagulant tablet approved in 1972 by Abbott as a small-molecule NDA. The generic name and specific indications are not documented in available data, though the oral tablet formulation suggests use in thrombotic or thromboembolic conditions. As a legacy product from the pre-modern anticoagulant era, it represents an older generation of anticoagulation therapy.
LOE Approaching
Approaching loss of exclusivity signals contraction; Abbott likely maintains minimal commercial infrastructure, with small teams focused on managed decline and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PANWARFIN represents a legacy product in managed decline with zero linked job openings, reflecting minimal hiring and limited career trajectory. Professionals joining this team should expect transition planning responsibilities, generic competitor management, and support for product phase-out rather than growth or innovation.
Brand Manager (Legacy/Transition)Field Sales Representative
Worked on PANWARFIN at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.